Supplementary Table 1. Patients' characteristics of all subjects

	Value	Range
Total number of patients	65	N/A
Age (years)	46.0 (40.0–54.5)	20.0–89.0
Sex, female/male (%)	24.6/75.4 (16–49)	N/A
Body mass index (kg/m^2)	26.3 (23.7–29.9)	19.9–44.6
Subtype of psoriasis, PV/PsA/PE/Pup (%)	64.6/24.6/6.2/4.6 (42/16/4/3)	N/A
Duration after the diagnosis of psoriasis (years)	12 (5–20)	0.5–43
PASI	8.7 (4.6–16.4)	1.2–33.8
PASI, <5/5–9/≥10 (%)	26.1/27.7/46.2 (17/18/30)	N/A
Experience of biological medication, biologic naïve/switching (%)	21.5/78.5 (14/51)	N/A
IL-17 inhibitor, secukinumab/Ixekizumab (%)	64.6/35.4 (42/23)	N/A
Alcoholic intake, 0/1–19/20–59/>60 g/day/no data (%)	40.0/4.6/3.1/1.5/50.8 (26/3/2/1/33)	N/A
Obesity, presence/absence (%)	66.2/33.8 (43/22)	N/A
Diabetes mellitus, presence/absence (%)	23.1/76.9 (15/50)	N/A
Hypertension, presence/absence (%)	30.8/69.2 (20/45)	N/A
Dyslipidemia, presence/absence (%)	13.8/86.2 (9/56)	N/A

Values are presented as median (interquartile range), range (minimum-maximum), or number.
N/A, not applicable; PV, psoriasis vulgaris; PsA, psoriatic arthritis; PE, psoriatic erythroderma; PuP, pustular psoriasis; PASI, psoriasis area and severity index; IL-17, interleukin-17.